|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC192 |
Gene summary for CCDC192 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC192 | Gene ID | 728586 |
| Gene name | coiled-coil domain containing 192 | |
| Gene Alias | LINC01183 | |
| Cytomap | 5q23.2-q23.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | P0DO97 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 728586 | CCDC192 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.29e-02 | 9.48e-02 | 0.0155 |
| 728586 | CCDC192 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.95e-03 | 1.52e-01 | 0.096 |
| 728586 | CCDC192 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.23e-04 | 4.45e-01 | 0.0131 |
| 728586 | CCDC192 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.31e-02 | 1.41e-01 | 0.0674 |
| 728586 | CCDC192 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.08e-02 | 3.06e-01 | 0.0112 |
| 728586 | CCDC192 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.38e-05 | 3.54e-01 | 0.0588 |
| 728586 | CCDC192 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.82e-07 | 3.19e-01 | 0.294 |
| 728586 | CCDC192 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 7.63e-05 | 9.46e-01 | 0.3487 |
| 728586 | CCDC192 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.09e-10 | 5.52e-01 | 0.281 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC192 | SNV | Missense_Mutation | novel | c.157N>A | p.Glu53Lys | p.E53K | P0DO97 | protein_coding | tolerated_low_confidence(0.74) | benign(0.005) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| CCDC192 | insertion | Frame_Shift_Ins | novel | c.498dupA | p.Leu167ThrfsTer4 | p.L167Tfs*4 | P0DO97 | protein_coding | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| CCDC192 | SNV | Missense_Mutation | novel | c.521C>T | p.Ala174Val | p.A174V | P0DO97 | protein_coding | deleterious(0.02) | benign(0.009) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.704N>T | p.Arg235Ile | p.R235I | P0DO97 | protein_coding | deleterious(0) | possibly_damaging(0.658) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.566N>G | p.Leu189Arg | p.L189R | P0DO97 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.43T>C | p.Trp15Arg | p.W15R | P0DO97 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.937) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.704N>T | p.Arg235Ile | p.R235I | P0DO97 | protein_coding | deleterious(0) | possibly_damaging(0.658) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.723A>C | p.Glu241Asp | p.E241D | P0DO97 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.809G>A | p.Gly270Glu | p.G270E | P0DO97 | protein_coding | tolerated(1) | benign(0.007) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CCDC192 | SNV | Missense_Mutation | novel | c.458N>G | p.Leu153Arg | p.L153R | P0DO97 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |